View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Soleno Therapeutics Inc: 1 director

A director at Soleno Therapeutics Inc sold 3,782 shares at 70.110USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Moody's Ratings downgrades Dollar General's senior unsecured notes rat...

Moody's Ratings (Moody's) today downgraded Dollar General Corporation's ("Dollar General") senior unsecured notes ratings to Baa3 from Baa2 and short-term commercial paper program rating to Prime-3 from Prime-2. The outlook changed to stable from negative. The downgrade reflects Dollar General's r...

 PRESS RELEASE

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat...

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYKAT XR (diazoxide choline) extended-release t...

 PRESS RELEASE

Oxbridge Re Holdings Limited Reports Fiscal 2024 Results

Oxbridge Re Holdings Limited Reports Fiscal 2024 Results GRAND CAYMAN, Cayman Islands, March 26, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (“Oxbridge Re” or the “Company”), which together with its subsidiaries, is engaged in the business of tokenized Real-World Assets (“RWAs”), initially in the form of tokenized reinsurance securities, and reinsurance business solutions to property and casualty insurers in the Gulf Coast region of the United States, today reported its results for the three months and year ended December 31, 2024. “SurancePlus is entering its third year in the Real World Asse...

 PRESS RELEASE

Oxbridge / SurancePlus to Speak at Uncorrelated Puerto Rico on April 1...

Oxbridge / SurancePlus to Speak at Uncorrelated Puerto Rico on April 1st GRAND CAYMAN, Cayman Islands, March 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), together with its subsidiary , is engaged in the tokenization of Real-World Assets (“RWAs”), initially with tokenized reinsurance securities and in providing reinsurance solutions to property and casualty insurers in the Gulf Coast region of the United States. The company today announced that its CEO and Chairman, , will participate as a panelist at the Uncorrelated Puerto Rico summit, taking place March 30th - April 1st at ...

 PRESS RELEASE

Oxbridge Re Announces 2024 Fourth Quarter Results on March 26, 2025

Oxbridge Re Announces 2024 Fourth Quarter Results on March 26, 2025 GRAND CAYMAN, Cayman Islands, March 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ), (the “Company”), which together with its subsidiaries is engaged in the business of tokenized Real-World Assets (“RWAs”), initially in the form of tokenized reinsurance securities, and reinsurance business solutions to property and casualty today, announced that it plans to hold a conference call on Wednesday March 26, 2025 at 4:30 p.m. Eastern Time to discuss results for the fourth quarter and year ending December 31, 2024. Financial results wi...

 PRESS RELEASE

Oxbridge / SurancePlus Announces Partnership with Plume, Expanding Acc...

Oxbridge / SurancePlus Announces Partnership with Plume, Expanding Access to Millions of Potential Investors GRAND CAYMAN, Cayman Islands, March 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), through its subsidiary , is engaged in the tokenization of Real-World Assets (“RWAs”), initially with tokenized reinsurance securities, today announced SurancePlus’ partnership with , a leading blockchain optimized for Real-World Asset Finance (RWAfi). This collaboration aims to significantly expand the distribution of 2025-2026 tokenized reinsurance securities - and - which target annu...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Oxbridge / SurancePlus to Attend Digital Asset Summit 2025 in New York

Oxbridge / SurancePlus to Attend Digital Asset Summit 2025 in New York GRAND CAYMAN, Cayman Islands, March 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), together with its subsidiary , is engaged in the tokenization of Real-World Assets (“RWAs”), initially with tokenized reinsurance securities, and in providing reinsurance solutions to property and casualty insurers in the Gulf Coast region of the United States, today announced its participation in Digital Asset Summit 2025, a leading institutional finance and blockchain event, taking place at Javits Center North in New York fr...

 PRESS RELEASE

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs ...

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers; Friedreich Ataxia (FA) Patient Dosing to Begin in mid-2025 Dosing Complete in DT-168 Phase 1 Healthy Volunteer Trial, with Data on Track for the First Half of 2025; Enrollment Target Achieved in Fuchs Endothelial Corneal Dystrophy (FECD) Observational Study Selection of Development Candidate for Myotonic Dystrophy Type-1 (DM1) Expected in 2025 Well-Capitalized with Cash and S...

 PRESS RELEASE

Oxbridge / SurancePlus Announces Two RWA Tokenized Reinsurance Offerin...

Oxbridge / SurancePlus Announces Two RWA Tokenized Reinsurance Offerings for its 2025 - 2026 Season: Targeting Returns of 20% and 42% GRAND CAYMAN, Cayman Islands, March 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), together with its subsidiary , is engaged in the tokenization of Real-World Assets (“RWAs”), initially with tokenized reinsurance securities, and in providing reinsurance solutions to property and casualty insurers in the Gulf Coast region of the United States, today announced the launch of its 2025 tokenized reinsurance offerings. For the first time, investors ca...

 PRESS RELEASE

Design Therapeutics to Participate in Leerink’s Global Healthcare Conf...

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference CARLSBAD, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during Leerink’s Global Healthcare Conference on Monday, March 10, 2025, at 1:40 p.m. ET in Miami. A live webcast of the fireside chat will be available and in the investors section of the company’s website at . The webcast will be archived for at l...

 PRESS RELEASE

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quart...

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2024. Full Year 2024 and Recent Corporate Highlights Regulatory New Drug Application (NDA) for diazoxide choline extended-release tablets (DCCR) for the treatm...

 PRESS RELEASE

Oxbridge Announces Pricing of $3.0 Million Registered Direct Offering ...

Oxbridge Announces Pricing of $3.0 Million Registered Direct Offering and Concurrent Private Placement  GRAND CAYMAN, Cayman Islands, Feb. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), together with its subsidiaries which is engaged in the business of tokenized Real-World Assets (“RWAs”) initially in the form of tokenized reinsurance securities, and reinsurance solutions to property and casualty insurers in the Gulf Coast region of the United State, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 705,884...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: February 20, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Oxbridge / SurancePlus to Speak at RWA DAY During ETHDenver 2025

Oxbridge / SurancePlus to Speak at RWA DAY During ETHDenver 2025 GRAND CAYMAN, Cayman Islands, Feb. 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“Oxbridge Re”), together with its subsidiary , is engaged in the tokenization of Real-World Assets (“RWAs”), initially with tokenized reinsurance securities, and in providing reinsurance solutions to property and casualty insurers in the Gulf Coast region of the United States, announced today that CEO and Chairman Jay Madhu will be a featured speaker at RWA DAY during ETHDenver 2025, a premier event focused on Real-World Asset (RWA) tokenization, mo...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: February 15, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch